Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New research supports efficacy of zincum gluconicum nasal gel

06.01.2003


Significant reduction in severity and duration of cold symptoms



New research confirms the efficacy of zincum gluconicum nasal gel in reducing the severity and duration of common cold symptoms when treatment is started as late as the second day of illness. The study, which appears in the January issue of QJM: An International Journal of Medicine, was the first trial on the naturally acquired common cold to extend initiation of treatment beyond the first 24 hours of illness.

"All previous evaluations of zincum gluconicum nasal gel’s effect on the naturally acquired common cold limited initiation of treatment to the first 24 hours of symptoms," explained Sherif B. Mossad, MD, FACP, FIDSA, Department of Infectious Diseases, Cleveland Clinic Foundation. "We now have findings to document a significant reduction in severity and duration of symptoms even when treatment is started as late as 48 hours after onset of illness."


Dr. Mossad said his study adds to a growing body of evidence supporting the effectiveness of zincum gluconicum nasal gel in reducing nasal drainage, nasal congestion, sore throat, and other symptoms typical of virus-induced rhinitis (inflammation of the mucous membranes of the nose). However, he noted that his study is the first to include microbiological confirmation of rhinovirus infection with polymerase chain reaction--a highly sensitive test--as well as information related to the specific time of perceived improvement of individual symptoms.

"Among the subset of patients with confirmed rhinovirus infection, the zinc nasal gel-treated patients experienced a 50% reduction in time to cold resolution when compared to the placebo group," said Dr. Mossad.

"This is great news for busy cold sufferers who cannot always treat their illness during that initial 24-hour period," said Carl J. Johnson, president and chief executive officer of Matrixx Initiatives, Inc., the makers of Zicam® cold remedy zinc nasal gel products. "It’s encouraging to see the building body of scientific evidence that supports the efficacy of using zinc nasal gel to combat the common cold."

Study Design

The randomized, double-blind, placebo-controlled study was supported by an unrestricted grant from Matrixx Initiatives, Inc. The population included 78 patients, between the ages of 18 and 55, who had cold symptoms, but were otherwise in good health.

Patients were enrolled within 24 to 48 hours of onset of three or more of the following symptoms: nasal drainage, sore throat, nasal congestion, sneezing, scratchy throat, hoarseness, cough, headache, muscle aches, and fever (oral temperature greater than 98.6º F).

Forty patients were randomized to treatment with zincum gluconicum nasal gel, and 38 patients were randomized to the placebo group. Rhinitis was documented by physical exam. Eighteen of the 78 patients (23%)--seven in the zincum gluconicum group and 11 in the placebo group--had rhinovirus infection confirmed by microbiological testing of specimens obtained by nasal irrigation.

Patients administered one dose of nasal gel per nostril, four times per day. Treatment endpoints were either resolution of symptoms or completion of the maximum 10-day treatment period. Patients in the zincum gluconicum group used a total daily dose of about 2.1 mg of elemental zinc. Patients in the placebo group used a compound identical to the treatment formulation in all aspects except the active ingredient. Patients were not permitted to use other cold remedies during the study period, such as nonsteroidal anti-inflammatory drugs (e.g., aspirin and ibuprofen), decongestants, antihistamines, or other zinc products.

Study Findings

The median duration of cold symptoms was significantly shorter in the zincum gluconicum group (4.3 days) compared to the placebo group (6 days). Other research has documented a reduction in duration of symptoms as great as 75% when the treatment period was extended to as long as 14 days.*

"Patients randomized to the zincum gluconicum nasal gel group experienced a marked reduction in median time to cold resolution and duration of most individual symptoms compared with the placebo group," said Dr. Mossad. "Signs and symptoms that showed the most reduction were nasal drainage, nasal congestion, hoarseness, and sore throat."

Dr. Mossad noted that the overall incidence of adverse effects was low, with no statistically significant difference between the treated and placebo groups. Occasional nasal stinging or burning sensation was the most common adverse effect reported in both groups.

"We were particularly impressed by the absence of reported gastrointestinal symptoms, such as nausea, that have been described by people using oral formulations of zinc," said Dr. Mossad.

About the Common Cold

According to the National Institutes of Health, people suffer an estimated one billion colds in the United States each year. Adults average about two to four colds a year, although the range varies widely. More than 200 different viruses are known to cause the symptoms of the common cold. Cold viruses are typically transmitted by any or all of the following:

  • Touching infectious respiratory secretions on skin and on environmental surfaces and then touching the eyes or nose.
  • Inhaling relatively large particles of respiratory secretions transported briefly in the air.
  • Inhaling droplet nuclei: smaller infectious particles suspended in the air for long periods of time.

The nose is the main portal of entry for cold viruses. The highest concentration of cold virus in nasal secretions occurs during the first three days of infection. This is when infected persons are most contagious.


About Matrixx Initiatives, Inc.

Matrixx Initiatives, Inc. is engaged in the development, manufacture and marketing of innovative drug delivery systems for over-the-counter (OTC) pharmaceuticals. Zicam, LLC, its wholly-owned subsidiary, produces, markets and sells Zicam® Cold Remedy nasal gel, a patented, homeopathic remedy that has been clinically proven to significantly reduce the duration and severity of the common cold. For more information regarding Matrixx products, go to www.zicam.com. To find out more about Matrixx Initiatives, Inc. (NASDAQ:MTXX), visit www.matrixxinc.com.

*Hirt M, Nobel S, Ernesto B. Zinc nasal gel for the treatment of common cold symptoms: A double blind, placebo-controlled trial. ENT J 2000;79:778-82

To schedule an interview with Dr. Mossad, contact The Cleveland Clinic Department of Public and Media Relations at 216-444-0141.

Robert Murphy | EurekAlert!

More articles from Health and Medicine:

nachricht On track to heal leukaemia
18.01.2017 | Universitätsspital Bern

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

A big nano boost for solar cells

18.01.2017 | Power and Electrical Engineering

Glass's off-kilter harmonies

18.01.2017 | Materials Sciences

Toward a 'smart' patch that automatically delivers insulin when needed

18.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>